Trial Profile
A Real World Cohort Study Evaluating The Safety And Efficacy Of Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With Ribavirin (3D + R) For 12 Weeks In Patients With Hepatitis C Virus (HCV) Genotype lb Infection And Compensated Cirrhosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2017 New trial record